RxDoctor Payments Data

Philip Fontenot, MD

Urology · Greenville, SCNPI 1790121424

Payments from drug & device makers

$4,163in general payments, 2019–2025

Across 121 payments — averaging $34.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Teleflex LLC$773
  • Neotract Inc.$330
  • AbbVie$209
  • Calyxo, Inc.$157
  • Astellas Pharma US Inc$153
  • plus $947 from 17 others

What the payments were for

  • Travel & lodging$1,04125%
  • Food & beverage$3,12275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,163 in reported general payments places this provider in the 50th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$356,726
Medicare patients
901
Services billed
21,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron113$87,078
GemtesaVibegron40$43,069
Tamsulosin Hcl1,005$12,957
Finasteride734$10,151
Mirabegron ErMirabegron14$7,068
Silodosin55$3,165
Testosterone40$3,078
Oxybutynin Chloride ErOxybutynin Chloride164$2,891
Alfuzosin Hcl ErAlfuzosin Hcl84$2,268
Tadalafil12$2,208
Estradiol29$2,174
Solifenacin Succinate29$2,153
Dutasteride52$2,030
Desmopressin Acetate24$1,521
Testosterone Cypionate54$1,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$153$87,078113 claims
Sumitomo Pharma America, Inc.Gemtesa$53$43,06940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 196 urology providers in South Carolina.

Other urology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →